Nema Health is a biotechnology company with a team of experienced professionals that includes experts in immunology, drug development, and business management. They are committed to bringing life-changing treatments to patients in need.

Nema Health is a spin-off biotech company that uses a proprietary technology to develop novel immunotherapies for cancer treatment. Nema Health has developed an innovative solution based on the use of personalized tumor neoantigens adjuvanted with DIF peptides. Through a natural activation of the immune system, this therapy can induce the destruction of the remaining tumor cells in the patient as well as prevent a future relapse.

Nema Health's solution has several competitive advantages derived from its physiologic mechanism of action: long-lasting/permanent effect, no secondary effects/toxicity, low-cost production, and complementarity with other therapies.

The DIF peptides-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. The next steps are pre-clinical regulatory and expanding the pipeline with new proof of concept based on Nema Health’s technology for additional indications.